Drugs / Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody
Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07149454 | Aug 2025 → May 2026 overdue | tetanus | Lanzhou Institute of Biological Products Co., Ltd | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07149454 ↗ |
| Modality | Monoclonal antibody | “Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody Injection” NCT07149454 ↗ |
| Route | Intramuscular | “intramuscular injection” NCT07149454 ↗ |